Reducing attrition in drug development: Smart loading preclinical safety assessment

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 341-347

  Roberts, Ruth A ^a   Kavanagh, Stefan L ^a   Mellor, Howard R ^a,b   Pollard, Christopher E ^a   Robinson, Sally ^a   Platz, Stefan J ^a  

^a ASTRAZENECA   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; GOOD LABORATORY PRACTICE; HEALTH CARE COST; HUMAN; NONHUMAN; REVIEW; RISK ASSESSMENT; TARGET ORGAN; TOXICOLOGY; TREATMENT FAILURE; ANIMAL; CARDIOTOXICITY; DRUG DESIGN; DRUG SCREENING; ECONOMICS; PROCEDURES; RESEARCH; STATISTICS AND NUMERICAL DATA; TOXICITY TESTING;

ANIMALS; CARDIOTOXICITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; RESEARCH; TOXICITY TESTS;

EID: 84896403739     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.014     Document Type: Review

References (20)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
2. F. Pammolli et al. The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
3. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. M. Herper The truly staggering cost of inventing new drugs Forbes 2012
5. M. Linder Clinical attrition due to biased preclinical assessments of potential efficacy Pharmacol. Ther. 115 2007 148 175
6. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
7. J. Arrowsmith, and P. Miller Trial watch: Phase II and Phase III attrition rates 2011-2012 Nat. Rev. Drug Discov. 12 2013 569
8. W.S. Redfern et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle The Toxicologist 114 2010 1081
9. P. Greaves et al. First dose of potential new medicines to humans: how animals help Nat. Rev. Drug Discov. 3 2004 226 236 (Pubitemid 38379989)
10. ABPI Why are animals needed in medicines research? 2011 Available at: http://www.abpi.org.uk/industry-info/new-medicines/Documents/ CaseStudy-WhyAnimalsNeeded.pdf
11. ICH M3(R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals 2009 Available at: http://www.ich.org/products/guidelines/multidisciplinary/article/ multidisciplinary-guidelines.html
12. ICH S9 Nonclinical evaluation for anticancer pharmaceuticals 2009 Available at: http://www.ich.org/products/guidelines/safety/article/safety- guidelines.html
13. A.R. Harmer et al. Validation of an in vitro contractility assay using canine ventricular myocytes Toxicol. Appl. Pharmacol. 260 2012 162 172
14. A.R. Harmer Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks J. Pharmacol. Toxicol. Methods 57 2007 30 41
15. C.E. Pollard An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk Br. J. Pharmacol. 159 2010 12 21
16. D. Smith et al. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog Reg. Toxicol. Pharmacol. 41 2005 95 101 (Pubitemid 40187178)
17. J. Leishman et al. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society Pharmacol. Toxicol. Methods 65 2012 93 101
18. H. Olson et al. Concordance of the toxicity of pharmaceuticals in humans and animals Regul. Toxicol. Pharmacol. 32 2000 56 67
19. K.K. Rozman, and J. Doull The role of time as a quantifiable variable of toxicity and the experiemental conditions when Haber's c × t product can be observed: implications for therapeutics J. Pharmacol. Exp. Ther. 296 2001 663 668 (Pubitemid 32187332)
20. NC3Rs/LASA Guidance on dose level selection for regulatory general toxicology studies for pharmaceuticals 2009 Available at: http://www.nc3rs.org. uk/document.asp?id=1317